Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease that may lead to alveolar destruction, impaired gas exchange, hyperinflation and reduced exercise capacity. It is a major cause of morbidity and mortality in Australia, with over 6300 deaths from the disease in 2020 and over 50 000 hospitalisations. 1,2 There are comprehensive guides for the management of COPD in Australia and New Zealand (COPD-X) 3 where the cornerstones of management include smoking cessation, inhaled pharmacotherapy, pulmonary rehabilitation and longterm oxygen therapy. However, endoscopic lung volume reduction (ELVR) is recommended in selected patients with severe emphysema. International guidelines for COPD management, such as the Global Initiative for Chronic Obstructive Lung Disease (GOLD 2023) 4 also recommend this with endobronchial valve therapy (EBV) being assessed as 'Evidence A'.The evidence for this is predominantly through multicentre randomised controlled international trials. [5][6][7][8] These studies suggest that the patients with COPD who benefit most from ELVR with EBV are those with severe or very severe heterogeneous emphysema and have significant gas trapping and complete or near-complete fissures of the targeted lobe (no collateral ventilation). 9 While ELVR with EBV has been performed in Australia since 2007, local evidence has been, until recently, focussed on mechanisms of action and assessment criteria. [10][11][12] However, there have now been two recent studies published with local data utilising accepted international guidelines for selection, which allows us to examine the local experience. The first by Sidhu et al. 13 was a retrospective consecutive review of 39 patients undergoing ELVR with EBV at two Victorian centres. The clinical improvement in lung function and exercise capacity were similar to published randomised controlled trials (RCTs), although postprocedure pneumothorax (36.5%) and repeat bronchoscopies (56.1%) for loss of effect or complications were higher than expected.The second study, published in this issue of the Internal Medicine Journal, is the paper by Brown et al. 14 This too is a retrospective study, but of 57 patients treated with EBVs at a single Australian centre (Royal Adelaide Hospital). Clinical results were also similar to those reported in international multicentre RCTs, 6,7,15 with targeted lung volume